このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION) (ACTION)

2026年5月5日 更新者:Faisal Sharif、University of Galway

Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes

The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.

The main questions it aims to answer are:

  • Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?
  • How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.

Participants will:

  • Provide informed consent and medical history/demographic information
  • Undergo blood sampling for cardiovascular and metabolic biomarkers
  • Have a resting ECG performed
  • Complete a detailed lifestyle and health questionnaire
  • Receive a non-invasive cardiac CT scan interpreted by an expert
  • Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality
  • Be referred for further clinical evaluation if clinically indicated 

調査の概要

詳細な説明

The ACTION Registry (Artificial Intelligence-assisted CT for Risk Stratification in Coronary Artery Disease) is a prospective, single-centre, observational patient registry conducted at the Clinical Research Facility, University Hospital Galway.

This registry is designed to systematically collect and integrate multimodal data from adults undergoing clinically indicated cardiac computed tomography (CT) to support advanced cardiovascular risk assessment using artificial intelligence (AI)-based approaches.

Registry Design and Procedures Eligible participants are consecutively enrolled at the time of referral for clinically indicated cardiac CT. Following informed consent, data are collected during a single baseline visit and supplemented by routine clinical data and follow-up information where available.

Registry procedures include:

  • Collection of demographic and clinical data from medical records
  • Blood sampling for cardiovascular and metabolic biomarkers
  • Resting electrocardiogram (ECG)
  • Structured questionnaires capturing lifestyle, cardiovascular history, and risk factors
  • Standard-of-care cardiac CT imaging acquisition and expert interpretation
  • Recording of medication use and clinically relevant interventions A subset of participants undergoing invasive imaging (e.g., optical coherence tomography) will have additional data collected for cross-modality comparison.

Data Collection and Registry Variables

The registry captures structured data across the following domains:

  • Clinical and demographic characteristics
  • Laboratory biomarkers
  • Imaging-derived parameters from cardiac CT
  • Lifestyle and behavioural factors
  • Treatment and medication data

All variables are defined in a standardized data dictionary, which specifies:

  • Variable definitions and formats
  • Source of data (e.g., imaging system, laboratory system, questionnaire)
  • Coding standards where applicable
  • Acceptable ranges and units Data Management and Quality Assurance All data are anonymised using unique participant identifiers and stored in secure, access-controlled electronic systems compliant with GDPR and institutional data governance policies.

A comprehensive quality assurance plan is implemented, including:

Data Validation and Entry Controls

  • Electronic data capture systems incorporate predefined validation rules
  • Range checks and logical consistency checks are applied at data entry
  • Automated queries are generated for missing, inconsistent, or out-of-range values Data Monitoring and Auditing
  • Periodic internal data reviews are conducted to ensure completeness and accuracy
  • Selected variables undergo source data verification against original records (e.g., imaging reports, laboratory systems, case report forms)
  • On-site or remote monitoring may be conducted in accordance with institutional policies Source Data Verification
  • A predefined proportion of records will be cross-checked with source documents
  • Discrepancies will be documented, reviewed, and resolved בהתאם standard procedures Standard Operating Procedures (SOPs)

Registry operations are governed by standardized procedures covering:

  • Participant recruitment and consent
  • Data collection and entry
  • Imaging acquisition and reporting
  • Laboratory data handling
  • Data management and security
  • Statistical analysis and reporting
  • Adverse event identification and reporting (if applicable)
  • Change management and protocol amendments Sample Size Considerations As an observational registry, the study aims to recruit a representative, real-world population of adults undergoing cardiac CT. The sample size is determined pragmatically based on recruitment feasibility and expected patient volume at the study site.

The anticipated sample size is sufficient to support:

  • Multivariable modelling for risk prediction
  • Subgroup analyses
  • Development and validation of AI-based models Handling of Missing Data

Missing or incomplete data may arise due to non-response, unavailable records, or technical limitations. The registry implements the following approach:

  • Real-time prompts to minimise missing data at entry
  • Documentation of reasons for missingness where available
  • Statistical handling using appropriate methods (e.g., multiple imputation, sensitivity analyses), depending on the extent and pattern of missing data Statistical Analysis Plan Analyses will be conducted in accordance with a predefined statistical analysis plan.

Approaches may include:

  • Descriptive statistics for baseline characteristics
  • Correlation analyses between imaging, clinical, and biomarker variables
  • Regression modelling for risk prediction and association analyses
  • Subgroup analyses across demographic and clinical strata
  • Cross-modality comparisons for imaging validation
  • Longitudinal analyses where follow-up data are available Model performance may be evaluated using appropriate metrics (e.g., discrimination, calibration, and reclassification measures).

Data Use and Future Applications

The registry is designed to support:

  • Clinical research and hypothesis generation
  • Development and validation of AI-based cardiovascular risk models
  • Integration of imaging and clinical data for precision medicine approaches An anonymised dataset will be maintained for future research, subject to governance and ethical approvals.

Ethical and Regulatory Considerations The registry is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the appropriate research ethics committee, and all participants will provide written informed consent prior to inclusion

研究の種類

観察的

入学 (推定)

10000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

All-comers adult population undergoing clinically indicated cardiac CT in routine clinical care

説明

Inclusion Criteria:

  • Adults aged ≥18 years
  • Undergoing clinically indicated cardiac CT
  • Able and willing to provide informed consent

Exclusion Criteria:

  • History of malignancy
  • Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)
  • Contraindications to iodinated contrast agents or CT imaging

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Cardiovascular risk stratification using AI-assisted cardiac CT
時間枠:Baseline
Assessment of cardiovascular risk based on AI-enhanced cardiac CT imaging, including coronary artery calcium scoring, plaque characterization, and integrated risk prediction using clinical and imaging data.
Baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Correlation between CT-derived plaque characteristics and haematological biomarkers
時間枠:Baseline
Association between imaging-derived plaque features and blood biomarkers (e.g., CRP, lipid profile, ApoB/ApoA-1 ratio).
Baseline
Concordance between coronary CT angiography (CCTA) and optical coherence tomography (OCT)
時間枠:Baseline (subset undergoing OCT)
Agreement between CT-derived plaque characteristics and OCT findings in a subset of participants.
Baseline (subset undergoing OCT)
Association between lifestyle factors and imaging-derived plaque risk features
時間枠:Baseline
ssociation between lifestyle factors (e.g., smoking, diet, occupation) and imaging-derived Parameters.
Baseline
Subgroup analyses of cardiovascular risk by demographic and clinical factors
時間枠:Baseline
Differences in imaging and risk profiles across subgroups (age, sex, comorbidities, hormonal history).
Baseline
Longitudinal changes in plaque composition in patients receiving statin therapy
時間枠:Baseline, 1 year, and annually up to 5 years
Evaluation of plaque progression or regression over time in participants on statin treatment.
Baseline, 1 year, and annually up to 5 years
Feasibility and utility of CT-derived fractional flow reserve (CT-FFR) and AI-based risk models
時間枠:Baseline
Assessment of the applicability and performance of CT-FFR and AI-based models in risk prediction.
Baseline

その他の成果指標

結果測定
メジャーの説明
時間枠
Development of an anonymized multimodal dataset for AI training and validation
時間枠:through study completion, up to 10 years
Creation of a secure dataset integrating imaging, clinical, biomarker, and lifestyle data for future AI development.
through study completion, up to 10 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Faisal Sharif, MBBS, PhD, FRCPI, FESC, FACC、University of Galway

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年12月21日

一次修了 (推定)

2032年12月21日

研究の完了 (推定)

2032年12月21日

試験登録日

最初に提出

2026年4月28日

QC基準を満たした最初の提出物

2026年5月5日

最初の投稿 (実際)

2026年5月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月11日

QC基準を満たした最後の更新が送信されました

2026年5月5日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する